摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2-hydroxy-4-methylphenyl)acetic acid tert-butyl ester | 295789-69-4

中文名称
——
中文别名
——
英文名称
(2-hydroxy-4-methylphenyl)acetic acid tert-butyl ester
英文别名
tert-butyl 2-(2-hydroxy-4-methylphenyl)acetate
(2-hydroxy-4-methylphenyl)acetic acid tert-butyl ester化学式
CAS
295789-69-4
化学式
C13H18O3
mdl
——
分子量
222.284
InChiKey
QYVGQUAMEQKHPA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    [4-Methyl-2-(phenylmethoxy)phenyl]acetic acid tert-butyl ester 、 氢气 作用下, 以 乙醇 为溶剂, 反应 10.0h, 以to give a crude product of (2-hydroxy-4-methylphenyl)acetic acid tert-butyl ester, 7.32 g (96%) as white solid的产率得到
    参考文献:
    名称:
    Phenylalanine derivatives
    摘要:
    本文披露了以下公式的苯丙氨酸衍生物化合物W-Y-(AA)n-Z,其中Y是苯丙氨酰基,AA是氨基酸,n是1到15的整数,取代变量W和Z如本文所述。这些化合物可用于抑制SH2与磷酸化蛋白结合,并抑制肿瘤细胞增殖。
    公开号:
    US07226991B1
点击查看最新优质反应信息

文献信息

  • Substituted Isoquinolinones and Quinazolinones
    申请人:BERGHAUSEN Joerg
    公开号:US20110230457A1
    公开(公告)日:2011-09-22
    The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH 2 or N—R 4 and X, R 1 , R 2 , R 4 , R 6 , R 7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    这项发明涉及公式(I)中的取代氮含有的双环杂环化合物,其中Z为CH2或N—R4,X、R1、R2、R4、R6、R7和n的定义如描述中所述。这类化合物适用于治疗由MDM2和/或MDM4的活性介导的疾病或疾病变体。
  • PHENYLALANINE DERIVATIVES
    申请人:Burke R. Terrence
    公开号:US20070219194A1
    公开(公告)日:2007-09-20
    The present invention provides phenylalanine derivatives that inhibit SH2 domain binding with a phosphoprotein. These derivatives include compounds of the formula: W—Y-(AA) n -Z wherein n is 0 to 15; Y is a phenylalanyl radical having a phenyl ring, an amine end, and a carboxyl end, the phenyl ring having one or more substituents, e.g., hydroxyl, carboxyl, formyl, carboxyalkyl, carboxyalkyloxy, dicarboxyalkyl, dicarboxyalkyloxy, dicarboxyhaloalkyl, dicarboxyhaloalkyloxy, and phosphonoalkyl, or phosphonohaloalkyl; W is a moiety attached to the nitrogen of Y and is, e.g., alkylcarbonyl, oxalyl, alkylaminooxalyl, arylaminooxalyl, arylalkylaminooxalyl, or alkoxyoxalyl; AA is an amino acid, the amine end of which is attached to the carboxyl end of Y; and Z is an arylalkylamino or arylheterocyclyl alkylamino; or a salt thereof; with the proviso that W is not arylalkylamino when the phenyl ring of phenylalanyl contains a phosphonoalkyl or phosphonohaloalkyl substituent at a position para to the alkylamido group and the ortho and meta positions are unsubstituted. The present invention further provides precursors suitable for preparing the phenylalanine derivatives and a method for the preparation of the precursors. The present invention further provides conjugates comprising a precursor and a conjugant that are covalently linked. These conjugates have biological and/or pharmacological properties.
    本发明提供苯丙酸衍生物,其抑制SH2域与磷酸化蛋白结合。这些衍生物包括以下公式的化合物:W—Y-(AA)n-Z,其中n为0至15;Y是具有苯环、胺端和羧基端的苯丙酰基基团,苯环具有一个或多个取代基,例如羟基、羧基、甲酰基、羧基烷基、羧基烷氧基、二羧基烷基、二羧基烷氧基、二羧基卤代烷基、二羧基卤代烷氧基、磷酸烷基或磷酸卤代烷基;W是连接到Y的氮上的基团,例如烷基羰基、草酰基、烷基基草酰基、芳基基草酰基、芳基烷基基草酰基或烷氧基草酰基;AA是一种氨基酸,其胺端连接到Y的羧基端;Z是芳基烷基基或芳基杂环基烷基基;或其盐;但是,当苯丙酰基的苯环在烷基酰基基团的对位上含有磷酸烷基或磷酸卤代烷基取代基,并且邻位和间位未取代时,W不是芳基烷基基。本发明还提供适用于制备苯丙酸衍生物的前体以及制备前体的方法。本发明还提供共价连接的前体和结合物的共轭物。这些共轭物具有生物和/或药理学性质。
  • Phenylanine derivatives
    申请人:The United States of America as represented by the Department of Health and Human Services
    公开号:US07825216B2
    公开(公告)日:2010-11-02
    The present invention provides phenylalanine derivatives that inhibit SH2 domain binding with a phosphoprotein. These derivatives include compounds of the formula: W—Y-(AA)n-Z wherein n is 0 to 15; Y is a phenylalanyl radical having a phenyl ring, an amine end, and a carboxyl end, the phenyl ring having one or more substituents, e.g., hydroxyl, carboxyl, formyl, carboxyalkyl, carboxyalkyloxy, dicarboxyalkyl, dicarboxyalkyloxy, dicarboxyhaloalkyl, dicarboxyhaloalkyloxy, and phosphonoalkyl, or phosphonohaloalkyl; W is a moiety attached to the nitrogen of Y and is, e.g., alkylcarbonyl, oxalyl, alkylaminooxalyl, arylaminooxalyl, arylalkylaminooxalyl, or alkoxyoxalyl; AA is an amino acid, the amine end of which is attached to the carboxyl end of Y; and Z is an arylalkylamino or arylheterocyclyl alkylamino; or a salt thereof; with the proviso that W is not arylalkylamino when the phenyl ring of phenylalanyl contains a phosphonoalkyl or phosphonohaloalkyl substituent at a position para to the alkylamido group and the ortho and meta positions are unsubstituted. The present invention further provides precursors suitable for preparing the phenylalanine derivatives and a method for the preparation of the precursors. The present invention further provides conjugates comprising a precursor and a conjugant that are covalently linked. These conjugates have biological and/or pharmacological properties.
    本发明提供了苯丙酸衍生物,可以抑制SH2结构域与磷酸化蛋白质的结合。这些衍生物包括以下化合物:W-Y-(AA)n-Z,其中n为0至15;Y是具有苯环、胺端和羧基端的苯丙酰基基团,苯环具有一个或多个取代基,例如羟基、羧基、甲酰基、羧基烷基、羧基烷氧基、二羧基烷基、二羧基烷氧基、二羧基卤代烷基、二羧基卤代烷氧基、磷酸烷基或磷酸卤代烷基;W是连接到Y的氮上的基团,例如烷基羰基、草酰基、烷基氧草酰基、芳基氧草酰基、芳基烷基氧草酰基或烷氧草酰基;AA是一种氨基酸,其胺端连接到Y的羧基端;Z是芳基烷基基或芳基杂环基烷基基;或其盐;但是,若苯丙酰基的苯环在离烷基酰胺基团的对位上含有磷酸烷基或磷酸卤代烷基取代基且邻位和间位未被取代,则W不是芳基烷基基。本发明还提供了适用于制备苯丙酸衍生物的前体物以及制备前体物的方法。本发明还提供了共价连接的前体和结合物的共轭物。这些共轭物具有生物和/或药理学性质。
  • SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES
    申请人:Novartis AG
    公开号:US20130281473A1
    公开(公告)日:2013-10-24
    The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH 2 or N—R 4 and X, R 1 , R 2 , R 4 , R 6 , R 7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    本发明涉及式(I)的取代氮含杂环的双环杂环化合物,其中Z是CH2或N-R4,X,R1,R2,R4,R6,R7和n的定义如说明书中所定义。这类化合物适用于治疗由MDM2和/或MDM4的活性或其变异体介导的疾病或疾病。
  • US7226991B1
    申请人:——
    公开号:US7226991B1
    公开(公告)日:2007-06-05
查看更多